On January 30, 2013, Vantage entered into an agreement with a US biopharmaceutical company with the intent of forming a future partnership with that company in order to develop, manufacture and commercialize biosimilar molecules. The cost of this partnership to us is to be determined at a future time upon further structuring of the agreement.